Metabolic confirms dosing study

Metabolic Pharmaceuticals (ASX:MBP) has confirmed that it will perform a further dosing study of its anti-obesity drug AOD9604, but a final decision on the protocol must await the outcome of partnering discussions

Analysis of the results from last year's Phase IIb study suggested that the optimal dosage was potentially below the lowest dose of 1 mg used in the trial, and the company is expecting to commence a dosage study looking at dosages below this level in the third quarter this year.

The trial is also likely to address the issue of whether weight loss continues at the same rate past 12 weeks.

According to a company update released today, the final protocol for the study will depend on whether Metabolic has partnered with a pharmaceutical company prior to the trial commencing. The company is currently in discussions with several pharma companies and has said that data packages from the Phase IIb trial have been requested by more than ten companies since the completion of the trial.